Effects of intravenous sivelestat sodium on prevention of acute respiratory distress syndrome in patients with sepsis: study protocol for a double-blind multicentre randomised controlled trial.

ABSTRACT:

Introduction

Sepsis is one of the most common risk factors for acute respiratory distress syndrome (ARDS). Neutrophil elastase (NE) is believed to be an important mediator of ARDS. When sepsis occurs, a large number of inflammatory factors are activated and released, which makes neutrophils migrate into the lung, eventually leading to the occurrence of ARDS. Sivelestat sodium is an NE inhibitor that can inhibit the inflammatory reaction during systemic inflammatory response syndrome and alleviate lung injury. Therefore, we hypothesise that intravenous sivelestat sodium may prevent the occurrence of ARDS in patients with sepsis.

Methods and analysis

This is a prospective, investigator-initiated, double-blind, adaptive, multicentre, randomised, controlled clinical trial with a

SUBMITTER: Ma S 

PROVIDER: S-EPMC10503371 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature